Home / Psoriasis / Psoriasis severity may be linked to an increased risk of death

Psoriasis severity may be linked to an increased risk of death

Patients with psoriasis covering 10% or more of their bodies are at almost double the risk of death, according to a study published in the Journal of Investigative Dermatology. It is the first study to link the severity of psoriasis to an increased risk of death using body surface area (BSA), an objective measure of disease severity, rather than according to treatment modalities (oral, injectable, or phototherapy).

Extent of psoriasis

Patients with a body surface area greater than 10% have a greatly increased risk of death compared with age- and gender-matched controls. Photo courtesy: Penn Medicine.

“It’s well established that psoriasis is associated with an increased risk for other comorbidities like chronic kidney disease, diabetes, and cardiovascular disease, but we don’t yet understand how the severity of psoriasis impacts future risk of major health problems,” said senior author Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Dr. Gelfand and colleagues used a database from the United Kingdom to identify 8,760 patients with psoriasis and 87,600 individuals without it. Patients’ general practitioners were sent a survey to determine the body surface area affected by psoriasis, and researchers used BSA, a measurement of the percentage of the body covered by psoriasis. The number of deaths in each group by person-years was determined.

About Dr. J. Kim

Dr Kim developed (and is continuing to develop) dermatology research news as we way from dermatologists to stay on top of the latest advances in the field of dermatology.

Check Also

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-1)

Study Description Go to  Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis. Condition or disease Intervention/treatment Phase Psoriasis Drug: Mirikizumab Drug: Placebo Phase 3 …

Leave a Reply

Your email address will not be published. Required fields are marked *